BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29212418)

  • 21. Validation of a Molecular Risk Score for Prognosis of Patients With Acute Promyelocytic Leukemia Treated With All-trans Retinoic Acid and Chemotherapy-containing Regimens.
    Hecht A; Doll S; Altmann H; Nowak D; Lengfelder E; Röllig C; Ehninger G; Spiekermann K; Hiddemann W; Weiß C; Hofmann WK; Nolte F; Platzbecker U
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):889-896.e5. PubMed ID: 28923666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.
    Kutny MA; Alonzo TA; Gerbing RB; Wang YC; Raimondi SC; Hirsch BA; Fu CH; Meshinchi S; Gamis AS; Feusner JH; Gregory JJ
    J Clin Oncol; 2017 Sep; 35(26):3021-3029. PubMed ID: 28767288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy.
    Ferrara F; Morabito F; Martino B; Specchia G; Liso V; Nobile F; Boccuni P; Di Noto R; Pane F; Annunziata M; Schiavone EM; De Simone M; Guglielmi C; Del Vecchio L; Lo Coco F
    J Clin Oncol; 2000 Mar; 18(6):1295-300. PubMed ID: 10715300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of acute promyelocytic leukemia with PETHEMA LPA 99 protocol: a Tunisian single center experience.
    Jeddi R; Ghédira H; Menif S; Ben Neji H; Ben Amor R; Kacem K; Aissaoui L; Bouteraâ W; Abdennebi Y; Raihane BL; Gouider E; Raouf H; Hèla BA; Saad A; Zaher B; Meddeb B
    Hematology; 2010 Aug; 15(4):204-9. PubMed ID: 20670478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group.
    Kutny MA; Moser BK; Laumann K; Feusner JH; Gamis A; Gregory J; Larson RA; Powell BL; Stock W; Willman CL; Woods WG; Meshinchi S
    Pediatr Blood Cancer; 2012 Oct; 59(4):662-7. PubMed ID: 22378655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy.
    Labrador J; Luño E; Vellenga E; Brunet S; González-Campos J; Chillón MC; Holowiecka A; Esteve J; Bergua J; González-Sanmiguel JD; Gil C; Tormo M; Salamero O; Manso F; Fernández I; de laSerna J; Moreno MJ; Pérez-Encinas M; Krsnik I; Ribera JM; Cervera J; Calasanz MJ; Boluda B; Sobas M; Lowenberg B; Sanz MA; Montesinos P
    Leuk Lymphoma; 2019 May; 60(5):1146-1155. PubMed ID: 30526152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group.
    Tallman MS; Kim HT; Montesinos P; Appelbaum FR; de la Serna J; Bennett JM; Deben G; Bloomfield CD; Gonzalez J; Feusner JH; Gonzalez M; Gallagher R; Miguel JD; Larson RA; Milone G; Paietta E; Rayon C; Rowe JM; Rivas C; Schiffer CA; Vellenga E; Shepherd L; Slack JL; Wiernik PH; Willman CL; Sanz MA
    Blood; 2010 Dec; 116(25):5650-9. PubMed ID: 20858857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
    Lou Y; Suo S; Tong H; Ye X; Wang Y; Chen Z; Qian W; Meng H; Mai W; Huang J; Tong Y; Jin J
    Leuk Res; 2013 Nov; 37(11):1451-6. PubMed ID: 23958062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
    de Botton S; Sanz MA; Chevret S; Dombret H; Martin G; Thomas X; Mediavilla JD; Recher C; Ades L; Quesnel B; Brault P; Fey M; Wandt H; Machover D; Guerci A; Maloisel F; Stoppa AM; Rayon C; Ribera JM; Chomienne C; Degos L; Fenaux P; ;
    Leukemia; 2006 Jan; 20(1):35-41. PubMed ID: 16307026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
    Hu J; Shen ZX; Sun GL; Chen SJ; Wang ZY; Chen Z
    Int J Hematol; 1999 Dec; 70(4):248-60. PubMed ID: 10643151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Therapeutic results with apl 93 protocol in acute promyelocytic leukemia (34 cases)].
    Jeddi R; Hdiji S; Kacem K; Ben Lakhal R; Aissaoui L; Ben Abid H; Belhadj Ali Z; Meddeb B
    Tunis Med; 2006 Nov; 84(11):717-20. PubMed ID: 17294898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA.
    Hernández JM; Martín G; Gutiérrez NC; Cervera J; Ferro MT; Calasanz MJ; Martínez-Climent JA; Luño E; Tormo M; Rayón C; Díaz-Mediavilla J; González M; González-San Miguel JD; Pérez-Equiza K; Rivas C; Esteve J; Alvarez Mdel C; Odriozola J; Ribera JM; Sanz MA;
    Haematologica; 2001 Aug; 86(8):807-13. PubMed ID: 11522536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
    Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
    Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.
    Adès L; Chevret S; Raffoux E; de Botton S; Guerci A; Pigneux A; Stoppa AM; Lamy T; Rigal-Huguet F; Vekhoff A; Meyer-Monard S; Maloisel F; Deconinck E; Ferrant A; Thomas X; Fegueux N; Chomienne C; Dombret H; Degos L; Fenaux P;
    J Clin Oncol; 2006 Dec; 24(36):5703-10. PubMed ID: 17116939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.
    Lehmann S; Ravn A; Carlsson L; Antunovic P; Deneberg S; Möllgård L; Derolf AR; Stockelberg D; Tidefelt U; Wahlin A; Wennström L; Höglund M; Juliusson G
    Leukemia; 2011 Jul; 25(7):1128-34. PubMed ID: 21502956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study.
    Slack JL; Arthur DC; Lawrence D; Mrózek K; Mayer RJ; Davey FR; Tantravahi R; Pettenati MJ; Bigner S; Carroll AJ; Rao KW; Schiffer CA; Bloomfield CD
    J Clin Oncol; 1997 May; 15(5):1786-95. PubMed ID: 9164186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy.
    de Botton S; Coiteux V; Chevret S; Rayon C; Vilmer E; Sanz M; de La Serna J; Philippe N; Baruchel A; Leverger G; Robert A; San Miguel J; Conde E; Sotto JJ; Bordessoule D; Fegueux N; Fey M; Parry A; Chomienne C; Degos L; Fenaux P
    J Clin Oncol; 2004 Apr; 22(8):1404-12. PubMed ID: 15084614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive factors of all-trans-retinoic acid related complications during induction therapy for acute promyelocytic leukemia.
    Jeddi R; Kacem K; Ben Neji H; Mnif S; Gouider E; Aissaoui L; Ben Amor R; Ben Lakhal R; Ben Abid H; Belhadjali Z; Meddeb B
    Hematology; 2008 Jun; 13(3):142-6. PubMed ID: 18702871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
    Testa U; Lo-Coco F
    Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.